Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.

Trial Profile

Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2010

At a glance

  • Drugs Candesartan cilexetil/hydrochlorothiazide (Primary)
  • Indications Diabetic nephropathies; Hypertension; Proteinuria
  • Focus Therapeutic Use
  • Acronyms CHILI-T2D
  • Most Recent Events

    • 01 May 2010 Results will be published in Clinical Drug Investigations.
    • 15 Apr 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top